← All trials
NCT03639701
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2017
- Primary completion
- Apr 1, 2024
- Completion date
- Apr 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Columbia UniversityLead sponsor
- Universidad Complutense de MadridCollaborator
- Columbia UniversityReponsible party - principal investigator
- Columbia UniversityOverall official - principal investigator
- University of SevilleCollaborator
- Universidad Carlos III MadridCollaborator
- CIBERERCollaborator
- Medical Research Council Mitochondrial Biology UnitCollaborator
- Muscular Dystrophy AssociationCollaborator
- Universidad Autonoma de BarcelonaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.